Estudo da Função e Estrutura Nervosa na Doença de Charcot-Marie-Tooth, Neuropatia Anti-MAG e CIDP (CMT-NFS)
Excitabilidade Axonal e Padrões de Ultrassom na Doença de Charcot-Marie-Tooth e Outras Doenças Desmielinizantes
The project aims to perform both conventional nerve-conduction studies and axonal-excitability assessments using the TRONDF protocol in patients with selected forms of Charcot-Marie-Tooth disease, with comparison to individuals affected by dysimmune, acquired neuropathies, specifically chronic inflammatory demyelinating polyneuropathy (CIDP) and anti-MAG-neuropathy. The study further includes the analysis of nerve fibers obtained from skin biopsy in patients with CMT, as well as ultrasound evaluation of nerves (from the wrist to the axilla) and of intrinsic hand muscles. Axonal-excitability techniques involve the delivery of two electrical stimuli to the nerve under investigation; both stimuli vary in intensity, whereas only the first, known as the conditioning stimulus, varies in duration. Changes in response amplitude are then measured as these stimulation parameters are systematically adjusted. Some preliminary studies have already suggested the effectiveness of this method in distinguishing CMT1A from certain forms of acquired demyelinating disease, including acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and CIDP. Despite the promising results, only a limited number of studies have so far been conducted in humans and mice, and no comprehensive and systematic study has yet been carried out describing the changes in axonal excitability in the various CMT subtypes, either in humans or in mouse models.
Visão geral do estudo
Status
Status
Condições
Condições
Descrição detalhada
Charcot-Marie-Tooth neuropathy (CMT) is the most prevalent hereditary neuromuscular disorder, estimated to affect 11.8 to 82.3 individuals per 100,000 in Europe. While genetic assessment is increasingly gaining significance, neurophysiology continues to play a crucial role in classifying CMT into axonal, intermediate or demyelinating forms. Despite its diagnostic importance, standard neurophysiology techniques may prove inadequate to reliably capture disease progression, advocating for the adoption of newer methodologies in the near future. Among these, axonal excitability testing, providing information about the properties of axonal membranes insight into the behaviour of voltage-gated ion channels, pump and exchangers involved in impulse conduction, could have potential additional diagnostic and prognostic value in neuromuscular disorder.
Axonal excitability techniques provide insights into ion channel function, serving as an in vivo surrogate markers of axonal membrane potential in human axons. Recent advancements in this field have standardized procedures, increased execution speed, and minimized patients' discomfort enabling routine clinical application. These advancements include the development of standardized semi-automated recording setups and the publication of international guidelines. It is plausible that progressive ion-channel dysfunction and spontaneous baseline depolarization of nerves maybe associated with disease severity and response to therapy (in patients with acquired polyneuropathies).
Investigators plan to study a series of patients with different types of CMT with this technique and compare results with diseased controls affected by dysimmune neuropathies and corresponding mouse models, by conventional nerve conduction studies, by electrical nerve stimulation to study neuronal excitability as below depicted, and by examining myelinated skin nerves by performing skin biopsy in a subset of patients.
Moreover, literature data demonstrate that nerve ultrasound supports the diagnosis and follow-up of neuromuscular disorders. In the context of neuropathies, nerve ultrasound enables an anatomical and structural evaluation that provides useful data for the differential diagnosis between hereditary and acquired forms. In particular, in Charcot-Marie-Tooth disease, nerve ultrasound allows the identification of pathognomonic patterns that can significantly guide genetic testing (e.g CMT1A).
In severe acquired forms, where the pathological process is so extensive that clear electrophysiological findings are not always present, nerve ultrasound can detect specific alterations that may help guiding the diagnosis. Moreover, nerve ultrasound can identify certain features that may suggest (and correlate with) the severity of the disease.
Muscle ultrasound in neuromuscular disorders is instead a more recent application. The detection of specific patterns of muscle involvement can suggest a possible regional distribution, described in some nosological entities. Furthermore, literature data show that the structural and ultrasound characteristics of the muscle correlate with the degree of strength deficit. Despite the increasing amount of literature in the field, no nerve or muscle ultrasound studies have yet been published on some acquired forms and rare forms of Charcot-Marie-Tooth disease. The collection and analysis of ultrasound data in these cases would allow for a broader understanding of the related pathological processes, potentially identifying patterns that support diagnosis and follow-up.
Collaborators for this project are the following: Inherited Neuropathy Consortium (INC); Prof. Christian Krarup (Dept of Clin. Neurophys., Rigshospitalet, Copenhagen, DK; Dept of Neuroscience, Univ. of Copenhagen, Copenhagen, DK); Prof. Mihai Moldovan (Dept of Neurol., North Zealand Hospital, Hillerød, DK; Dept of Clin. Neurophys., Rigshospitalet, Copenhagen, DK; Dept of Neuroscience, Univ. of Copenhagen, Copenhagen, DK); Prof. Hatice Tankisi (Aarhus University Hospital, Department of Clinical Neurophysiology, Aarhus, Denmark; Aarhus University, Department of Clinical Medicine, Aarhus, Denmark)
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Davide Pareyson, MD
- Número de telefone: + 39 02.2394
- E-mail: davide.pareyson@istituto-besta.it
Estude backup de contato
- Nome: Amedeo De Grado, M.D.
- Número de telefone: 02.2394
- E-mail: amedeo.degrado@istituto-besta.it
Locais de estudo
-
-
-
Milan, Itália, 20133
- Recrutamento
- Fondazione IRCCS Istituto Neurologico Carlo Besta
-
Contato:
- Davide Pareyson, MD
- Número de telefone: + 39 02.2394
- E-mail: davide.pareyson@istituto-besta.it
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
- A minimum of 30 patients with a genetically confirmed diagnosis of CMT
- At least 15 patients diagnosed with either Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or anti-myelin associated glycoprotein (MAG) polyneuropathy as a disease control group.
Descrição
Inclusion Criteria:
-
The subject is ≥ 18 years old.
AND:
-
A genetically confirmed diagnosis of one of the several CMT subtypes (i.e., CMT1A, CMT1B, CMTX1, CMT2I/J, CMT4B, CMT4D and CMT4J) OR
-
A clinical diagnosis of either Chronic Inflammatory Demyelinating Polyneuropathy or anti-MAG polyneuropathy
Exclusion Criteria:
- Known neuropathy from another cause (e.g., diabetes, chronic renal insufficiency, medications, alcohol), including previous carpal tunnel syndrome surgery.
- History of exposure to chemotherapeutic agents (e.g., bortezomib, vincristine, cisplatin, taxol, vedotin/auromycin-conjugated antibodies), or other medications (e.g., disulfuram, thalidomide, voriconizole, chronic colchicine use) that can cause neuropathy, active alcohol abuse.
- History of cancer, other than skin cancer, within 5 years prior to enrollment.
- Pregnancy or nursing.
- Known systemic disease that predisposes to neuropathy.
- Other central nervous system diseases.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: OTHER
- Perspectivas de Tempo: PROSPECTIVE
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Strength-Duration Time Constant
Prazo: 2 years
|
Strength-duration time constant (SDTC, ms) measured using threshold tracking nerve excitability testing in participants with genetically defined Charcot-Marie-Tooth disease subtypes and acquired immune-mediated neuropathies (CIDP and anti-MAG neuropathy). |
2 years
|
|
Recovery Cycle of Nerve Excitability Parameters
Prazo: 2 years
|
Recovery cycle of nerve excitability parameters measured using threshold tracking nerve excitability testing in participants with genetically defined Charcot-Marie-Tooth disease subtypes and acquired immune-mediated neuropathies (CIDP and anti-MAG neuropathy), including superexcitability and late subexcitability (% threshold change) |
2 years
|
|
Threshold Electrotonus
Prazo: 2 years
|
Threshold Electrotonus (TE, % threshold change at specified time intervals) measured using threshold tracking nerve excitability testing in participants with genetically defined Charcot-Marie-Tooth disease subtypes and acquired immune-mediated neuropathies (CIDP and anti-MAG neuropathy). |
2 years
|
|
Current-Threshold (I/V) Relationship
Prazo: 2 years
|
Current-threshold (I/V) relationship parameters (e.g., slope of threshold change versus polarizing current) measured using threshold tracking nerve excitability testing in participants with genetically defined Charcot-Marie-Tooth disease subtypes and acquired immune-mediated neuropathies (CIDP and anti-MAG neuropathy). |
2 years
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Peripheral nerve cross-sectional area by ultrasound
Prazo: 2 years
|
Cross-sectional area (CSA, mm²) of the median and ulnar nerves measured by ultrasound from the wrist to the axilla in participants with Charcot-Marie-Tooth disease, CIDP, and anti-MAG neuropathy. |
2 years
|
|
Muscle thickness by ultrasound
Prazo: 2 years
|
Muscle thickness (mm) of the abductor pollicis brevis, abductor digiti minimi, and first dorsal interosseous muscles measured by ultrasound in participants with Charcot-Marie-Tooth disease, CIDP, and anti-MAG neuropathy. |
2 years
|
|
Muscle echogenicity by ultrasound (Heckmatt scale)
Prazo: 2 years
|
Muscle echogenicity graded using the Heckmatt scale (grades 1-4) in the abductor pollicis brevis, abductor digiti minimi, and first dorsal interosseous muscles. Heckmatt scale grading: Grade 1: normal Grade 2: increased muscle echogenicity with preserved architecture and normal bone reflection Grade 3: increased echogenicity with partial loss of architecture and reduced bone reflection Grade 4: markedly increased echogenicity with complete loss of architecture and absent bone reflection |
2 years
|
|
Correlation of ultrasound parameters with clinical and electrophysiological measures
Prazo: 2 years
|
Correlation between ultrasound parameters (nerve CSA, muscle thickness, and Heckmatt grade) and clinical severity measured by CMTNS/CMTES and axonal excitability parameters. |
2 years
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Axonal excitability strength-duration time constant in mouse models
Prazo: 2 years
|
Strength-duration time constant (SDTC, ms) measured using threshold tracking nerve excitability testing in TM/TM mice carrying the MPZ T124M mutation, C3-PMP22 transgenic mice, and wild-type control mice. |
2 years
|
|
Recovery Cycle of excitability parameters in mouse models
Prazo: 2 years
|
Recovery Cycle of excitability parameters, including relative refractory period (ms), superexcitability (% threshold change), and late subexcitability (% threshold change), measured in TM/TM mice, C3-PMP22 transgenic mice, and wild-type control mice. |
2 years
|
|
Threshold Electrotonus in mouse models
Prazo: 2 years
|
Threshold Electrotonus (TE, % threshold change at specified time intervals) measured in TM/TM mice, C3-PMP22 transgenic mice, and wild-type control mice. |
2 years
|
|
Current-threshold (I/V) relationship in mouse models
Prazo: 2 years
|
Current-threshold (I/V) relationship parameters (e.g., slope of threshold change versus polarizing current) measured in TM/TM mice, C3-PMP22 transgenic mice, and wild-type control mice. |
2 years
|
|
Cross-species comparison of axonal excitability parameters
Prazo: 2 years
|
Comparison of axonal excitability parameters (SDTC, Recovery Cycle, TE, and I/V relationship) between mouse models and homologous human disease cohorts. |
2 years
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Davide Pareyson, MD, Fondazione IRCCS Istituto Neurologico Carlo Besta
Publicações e links úteis
Publicações Gerais
- Pareyson D, Marchesi C. Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol. 2009 Jul;8(7):654-67. doi: 10.1016/S1474-4422(09)70110-3.
- Bostock H, Cikurel K, Burke D. Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve. 1998 Feb;21(2):137-58. doi: 10.1002/(sici)1097-4598(199802)21:23.0.co;2-c.
- Shahrizaila N, Noto Y, Simon NG, Huynh W, Shibuya K, Matamala JM, Dharmadasa T, Devenney E, Kennerson ML, Nicholson GA, Kiernan MC. Quantitative muscle ultrasound as a biomarker in Charcot-Marie-Tooth neuropathy. Clin Neurophysiol. 2017 Jan;128(1):227-232. doi: 10.1016/j.clinph.2016.11.010. Epub 2016 Nov 21.
- Padua L, Granata G, Sabatelli M, Inghilleri M, Lucchetta M, Luigetti M, Coraci D, Martinoli C, Briani C. Heterogeneity of root and nerve ultrasound pattern in CIDP patients. Clin Neurophysiol. 2014 Jan;125(1):160-5. doi: 10.1016/j.clinph.2013.07.023. Epub 2013 Oct 5.
- Noto Y, Shiga K, Tsuji Y, Mizuta I, Higuchi Y, Hashiguchi A, Takashima H, Nakagawa M, Mizuno T. Nerve ultrasound depicts peripheral nerve enlargement in patients with genetically distinct Charcot-Marie-Tooth disease. J Neurol Neurosurg Psychiatry. 2015 Apr;86(4):378-84. doi: 10.1136/jnnp-2014-308211. Epub 2014 Aug 4.
- Schreiber S, Oldag A, Kornblum C, Kollewe K, Kropf S, Schoenfeld A, Feistner H, Jakubiczka S, Kunz WS, Scherlach C, Tempelmann C, Mawrin C, Dengler R, Schreiber F, Goertler M, Vielhaber S. Sonography of the median nerve in CMT1A, CMT2A, CMTX, and HNPP. Muscle Nerve. 2013 Mar;47(3):385-95. doi: 10.1002/mus.23681. Epub 2013 Feb 4.
- Manganelli F, Nolano M, Pisciotta C, Provitera V, Fabrizi GM, Cavallaro T, Stancanelli A, Caporaso G, Shy ME, Santoro L. Charcot-Marie-Tooth disease: New insights from skin biopsy. Neurology. 2015 Oct 6;85(14):1202-8. doi: 10.1212/WNL.0000000000001993. Epub 2015 Sep 11.
- Nobbio L, Visigalli D, Radice D, Fiorina E, Solari A, Lauria G, Reilly MM, Santoro L, Schenone A, Pareyson D; CMT-TRIAAL Group. PMP22 messenger RNA levels in skin biopsies: testing the effectiveness of a Charcot-Marie-Tooth 1A biomarker. Brain. 2014 Jun;137(Pt 6):1614-20. doi: 10.1093/brain/awu071. Epub 2014 May 8.
- Burke D, Kiernan MC, Bostock H. Excitability of human axons. Clin Neurophysiol. 2001 Sep;112(9):1575-85. doi: 10.1016/s1388-2457(01)00595-8.
- Kiernan MC, Burke D, Andersen KV, Bostock H. Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve. 2000 Mar;23(3):399-409. doi: 10.1002/(sici)1097-4598(200003)23:33.0.co;2-g.
- Moldovan M, Alvarez S, Pinchenko V, Klein D, Nielsen FC, Wood JN, Martini R, Krarup C. Na(v)1.8 channelopathy in mutant mice deficient for myelin protein zero is detrimental to motor axons. Brain. 2011 Feb;134(Pt 2):585-601. doi: 10.1093/brain/awq336. Epub 2010 Dec 17.
- Rosberg MR, Alvarez S, Klein D, Nielsen FC, Martini R, Levinson SR, Krarup C, Moldovan M. Progression of motor axon dysfunction and ectopic Nav1.8 expression in a mouse model of Charcot-Marie-Tooth disease 1B. Neurobiol Dis. 2016 Sep;93:201-14. doi: 10.1016/j.nbd.2016.05.014. Epub 2016 May 20.
- Nasu S, Misawa S, Nakaseko C, Shibuya K, Isose S, Sekiguchi Y, Mitsuma S, Ohmori S, Iwai Y, Beppu M, Shimizu N, Ohwada C, Takeda Y, Fujimaki Y, Kuwabara S. Bortezomib-induced neuropathy: axonal membrane depolarization precedes development of neuropathy. Clin Neurophysiol. 2014 Feb;125(2):381-7. doi: 10.1016/j.clinph.2013.07.014. Epub 2013 Aug 21.
- Lin CS, Krishnan AV, Park SB, Kiernan MC. Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Arch Neurol. 2011 Jul;68(7):862-9. doi: 10.1001/archneurol.2011.137.
- Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain. 2009 Oct;132(Pt 10):2712-23. doi: 10.1093/brain/awp219. Epub 2009 Sep 10.
- Sung JY, Kuwabara S, Kaji R, Ogawara K, Mori M, Kanai K, Nodera H, Hattori T, Bostock H. Threshold electrotonus in chronic inflammatory demyelinating polyneuropathy: correlation with clinical profiles. Muscle Nerve. 2004 Jan;29(1):28-37. doi: 10.1002/mus.10516.
- Moldovan M, Pisciotta C, Pareyson D, Krarup C. Myelin protein zero gene dose dependent axonal ion-channel dysfunction in a family with Charcot-Marie-Tooth disease. Clin Neurophysiol. 2020 Oct;131(10):2440-2451. doi: 10.1016/j.clinph.2020.06.034. Epub 2020 Aug 6.
- Vanhees L, Aubert A, Fagard R, Hespel P, Amery A. Influence of beta 1- versus beta 2-adrenoceptor blockade on left ventricular function in humans. J Cardiovasc Pharmacol. 1986 Sep-Oct;8(5):1086-91. doi: 10.1097/00005344-198609000-00030.
- Nodera H, Bostock H, Kuwabara S, Sakamoto T, Asanuma K, Jia-Ying S, Ogawara K, Hattori N, Hirayama M, Sobue G, Kaji R. Nerve excitability properties in Charcot-Marie-Tooth disease type 1A. Brain. 2004 Jan;127(Pt 1):203-11. doi: 10.1093/brain/awh020. Epub 2003 Nov 7.
- Kiernan MC, Bostock H, Park SB, Kaji R, Krarup C, Krishnan AV, Kuwabara S, Lin CS, Misawa S, Moldovan M, Sung J, Vucic S, Wainger BJ, Waxman S, Burke D. Measurement of axonal excitability: Consensus guidelines. Clin Neurophysiol. 2020 Jan;131(1):308-323. doi: 10.1016/j.clinph.2019.07.023. Epub 2019 Aug 2.
- Laura M, Pipis M, Rossor AM, Reilly MM. Charcot-Marie-Tooth disease and related disorders: an evolving landscape. Curr Opin Neurol. 2019 Oct;32(5):641-650. doi: 10.1097/WCO.0000000000000735.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do Sistema Nervoso
- Processos Patológicos
- Doenças Neuromusculares
- Doença crônica
- Atributos da doença
- Doenças Genéticas, Congênitas
- Doenças autoimunes
- Doenças do sistema imunológico
- Doenças do Sistema Nervoso Periférico
- Doenças Autoimunes do Sistema Nervoso
- Doenças Desmielinizantes
- Doenças Neurodegenerativas
- Anomalias congénitas
- Distúrbios Heredodegenerativos, Sistema Nervoso
- Malformações do Sistema Nervoso
- Polineuropatias
- Polirradiculoneuropatia
- Neuropatia Sensorial e Motora Hereditária
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Condições Patológicas, Sinais e Sintomas
- Doença de Charcot-Marie-Tooth
- Polirradiculoneuropatia Inflamatória Crônica Desmielinizante
- Doença de Charcot-Marie-Tooth, ligada ao cromossoma X, tipo 1
- Doença de Charcot-Marie-Tooth, Tipo 4B2
- Neuropatia hereditária motora e sensorial, tipo LOM
Outros números de identificação do estudo
Outros números de identificação do estudo
- CMT-NFS
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .